文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

二甲双胍和二甲双胍/利拉利汀对糖尿病前期患者肠道微生物群的影响。

Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes.

机构信息

Human Systems Biology Laboratory. Instituto Nacional de Medicina Genómica (INMEGEN), México City, Mexico.

Programa de Doctorado en Ciencias Médicas, Odontológicas y de la Salud, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico.

出版信息

Sci Rep. 2024 Apr 27;14(1):9678. doi: 10.1038/s41598-024-60081-y.

DOI:10.1038/s41598-024-60081-y
PMID:38678119
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11055900/
Abstract

Lifestyle modifications, metformin, and linagliptin reduce the incidence of type 2 diabetes (T2D) in people with prediabetes. The gut microbiota (GM) may enhance such interventions' efficacy. We determined the effect of linagliptin/metformin (LM) vs metformin (M) on GM composition and its relationship to insulin sensitivity (IS) and pancreatic β-cell function (Pβf) in patients with prediabetes. A cross-sectional study was conducted at different times: basal, six, and twelve months in 167 Mexican adults with prediabetes. These treatments increased the abundance of GM SCFA-producing bacteria M (Fusicatenibacter and Blautia) and LM (Roseburia, Bifidobacterium, and [Eubacterium] hallii group). We performed a mediation analysis with structural equation models (SEM). In conclusion, M and LM therapies improve insulin sensitivity and Pβf in prediabetics. GM is partially associated with these improvements since the SEM models suggest a weak association between specific bacterial genera and improvements in IS and Pβf.

摘要

生活方式的改变、二甲双胍和利拉格列汀可降低糖尿病前期人群 2 型糖尿病（T2D）的发病率。肠道微生物群（GM）可能增强这些干预措施的疗效。我们确定了利拉格列汀/二甲双胍（LM）与二甲双胍（M）对糖尿病前期患者 GM 组成的影响，以及其与胰岛素敏感性（IS）和胰岛β细胞功能（Pβf）的关系。在 167 名墨西哥糖尿病前期成年人中，分别在基线、6 个月和 12 个月进行了横断面研究。这些治疗方法增加了 GM 产生短链脂肪酸的细菌 M（Fusicatenibacter 和 Blautia）和 LM（Roseburia、双歧杆菌和[Eubacterium] hallii 组）的丰度。我们使用结构方程模型（SEM）进行了中介分析。总之，M 和 LM 疗法可改善糖尿病前期患者的胰岛素敏感性和 Pβf。GM 与这些改善部分相关，因为 SEM 模型表明特定细菌属与 IS 和 Pβf 的改善之间存在弱关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/34e57d40137f/41598_2024_60081_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/af20e0e98e67/41598_2024_60081_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/8961ef730d95/41598_2024_60081_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/5b422ed9c8b1/41598_2024_60081_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/69bcafabf733/41598_2024_60081_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/34e57d40137f/41598_2024_60081_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/af20e0e98e67/41598_2024_60081_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/8961ef730d95/41598_2024_60081_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/5b422ed9c8b1/41598_2024_60081_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/69bcafabf733/41598_2024_60081_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c4d/11055900/34e57d40137f/41598_2024_60081_Fig5_HTML.jpg

相似文献

[1]
Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes.

Sci Rep. 2024-4-27

[2]
The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.

Metabolism. 2019-12-28

[3]
Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle.

Sci Rep. 2021-4-22

[4]
Metformin exerts anti-obesity effect via gut microbiome modulation in prediabetics: A hypothesis.

Med Hypotheses. 2017-7

[5]
Aberrant intestinal microbiota in individuals with prediabetes.

Diabetologia. 2018-1-29

[6]
Metformin-induced changes of the gut microbiota in patients with type 2 diabetes mellitus: results from a prospective cohort study.

Endocrine. 2024-9

[7]
Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.

Endocr Pract. 2012

[8]
Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.

Diabet Med. 2016-7

[9]
Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men.

Metabolism. 2024-8

[10]
Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut.

Diabetes Care. 2016-11-14

引用本文的文献

[1]
Vildagliptin modulates the microbiota and induces an immunometabolic profile compatible with neuroprotection in type 2 diabetes.

Sci Rep. 2025-7-31

[2]
Probiotic Supplementation Improves Gut Microbiota in Chronic Metabolic and Cardio-Cerebrovascular Diseases Among Chinese Adults over 60: Study Using Cross-Sectional and Longitudinal Cohorts.

Microorganisms. 2025-6-27

[3]
Intestinal Microbiota Composition in Patients with Type 2 Diabetes and Effects of Oral Antidiabetics.

J Clin Med. 2025-4-17

[4]
Diabetes and gut microbiome.

Front Microbiol. 2025-1-7

[5]
The characteristics of intestinal microbiota in patients with type 2 diabetes and the correlation with the percentage of T-helper cells.

Front Microbiol. 2024-9-27

[6]
A new perspective in intestinal microecology: lifting the veil of exercise regulation of cardiometabolic diseases.

Gut Microbes. 2024

本文引用的文献

[1]
mb-PHENIX: diffusion and supervised uniform manifold approximation for denoizing microbiota data.

Bioinformatics. 2023-12-1

[2]
Stochasticity causes high β-diversity and functional divergence of bacterial assemblages in closed systems.

Ecology. 2023-4

[3]
Unique Pakistani gut microbiota highlights population-specific microbiota signatures of type 2 diabetes mellitus.

Gut Microbes. 2022

[4]
Type 2 diabetes, gut microbiome, and systems biology: A novel perspective for a new era.

Gut Microbes. 2022

[5]
Abridged for Primary Care Providers.

Clin Diabetes. 2022-1

[6]
Gut microbiota-derived metabolites are novel targets for improving insulin resistance.

World J Diabetes. 2022-1-15

[7]
Gut Microbiota and Complications of Type-2 Diabetes.

Nutrients. 2021-12-30

[8]
Gut microbiota of patients with type 2 diabetes and gastrointestinal intolerance to metformin differs in composition and functionality from tolerant patients.

Biomed Pharmacother. 2022-1

[9]
Prospects for clinical applications of butyrate-producing bacteria.

World J Clin Pediatr. 2021-9-9

[10]
Next Generation Microbiome Research: Identification of Keystone Species in the Metabolic Regulation of Host-Gut Microbiota Interplay.

Front Cell Dev Biol. 2021-9-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索